HC Wainwright Has Optimistic Opinion of RNAC FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate to a loss of $2.28 per share from a projected loss of $2.91, and maintained a Buy rating with a $25 price target.
• Cartesian reported a quarterly loss of $0.38 per share, beating the consensus estimate of a $1.01 loss by $0.63.
• Shares were down 6.8% and opened at $7.02; analysts’ overall consensus rating is Moderate Buy, with an average price target of $32.60.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of Cartesian Therapeutics in a note issued to investors on Friday, November 6th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($2.28) per share for the year, up from their prior estimate of ($2.91). HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for Cartesian Therapeutics' current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Cartesian Therapeutics' Q4 2026 earnings at ($1.05) EPS, Q1 2027 earnings at ($1.08) EPS, Q2 2027 earnings at ($0.94) EPS, Q3 2027 earnings at ($0.81) EPS, Q4 2027 earnings at ($0.82) EPS and FY2027 earnings at ($3.61) EPS.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.63.

RNAC has been the topic of several other reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cartesian Therapeutics in a research note on Wednesday, September 9th. Needham & Company LLC reissued a "buy" rating and set a $40.00 price objective on shares of Cartesian Therapeutics in a research report on Tuesday, September 29th. Zacks Research upgraded Cartesian Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, July 29th. Wedbush reaffirmed an "outperform" rating and issued a $38.00 target price on shares of Cartesian Therapeutics in a report on Tuesday, August 18th. Finally, Wall Street Zen raised Cartesian Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cartesian Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $32.60.

Cartesian Therapeutics Stock Down 6.8%

NASDAQ RNAC opened at $7.02 on Tuesday. The company has a fifty day simple moving average of $7.35 and a 200 day simple moving average of $7.64. Cartesian Therapeutics has a 1 year low of $5.60 and a 1 year high of $11.00.

Institutional Trading of Cartesian Therapeutics

A number of hedge funds have recently modified their holdings of RNAC. Sei Investments Co. acquired a new stake in shares of Cartesian Therapeutics during the 1st quarter worth approximately $78,000. Bank of New York Mellon Corp acquired a new position in shares of Cartesian Therapeutics in the second quarter valued at $332,000. Renaissance Technologies LLC raised its stake in shares of Cartesian Therapeutics by 63.7% in the first quarter. Renaissance Technologies LLC now owns 67,300 shares of the company's stock valued at $414,000 after purchasing an additional 26,200 shares in the last quarter. Privium Fund Management B.V. raised its stake in shares of Cartesian Therapeutics by 2.2% in the third quarter. Privium Fund Management B.V. now owns 155,000 shares of the company's stock valued at $1,118,000 after purchasing an additional 3,325 shares in the last quarter. Finally, Squarepoint Ops LLC raised its stake in shares of Cartesian Therapeutics by 0.7% in the second quarter. Squarepoint Ops LLC now owns 2,254,619 shares of the company's stock valued at $23,493,000 after purchasing an additional 16,133 shares in the last quarter. Institutional investors own 86.95% of the company's stock.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc NASDAQ: RNAC is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company's platform is designed to program a patient's own immune cells with messenger RNA, enabling the development of cell therapies that are intended to provide targeted treatment without permanent genetic modification.

Cartesian's lead product candidate is Descartes-08, an autologous CAR T-cell therapy that targets B-cell maturation antigen (BCMA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.